<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01451489</url>
  </required_header>
  <id_info>
    <org_study_id>NJCT-1101</org_study_id>
    <nct_id>NCT01451489</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis</brief_title>
  <acronym>FSGS</acronym>
  <official_title>A Randomized,Multicentre,Prospective Study on the Tacrolimus(FK506)for Focal Segmental Glomerulosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective,multicentre study to compare the efficacy, safety, tolerability and
      relapse of FK506 versus CTX in the treatment of severe Focal Segmental Glomerulosclerosis
      (FSGS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Using the response rate and completely response time to compare the efficacy of FK506
           versus CTX therapy for the severe FSGS patients.

        2. To compare the safety and tolerability of FK506 versus CTX for the severe FSGS patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The recruitment of subject is very difficult
  </why_stopped>
  <start_date type="Actual">October 13, 2011</start_date>
  <completion_date type="Actual">October 29, 2016</completion_date>
  <primary_completion_date type="Actual">March 23, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the rates of the complete remission during the induction phase</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the total remission rates</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>FSGS</condition>
  <arm_group>
    <arm_group_label>Cyclophosphamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CTX</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FK506</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.05-0.1mg/kg/d;adjust the dose according the serum concentration(aim 5-10ng/ml),maximum dose 6mg/day;divided in twice, interval 12 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FK506</intervention_name>
    <description>FK506:0.05-0.1mg/kg/d</description>
    <arm_group_label>FK506</arm_group_label>
    <other_name>Tacrolimus,Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>CTX 750mg/m2 per month in the induction phase,then 750mg/m2 every 2 month for 3 times,then 750mg/m2 every 3 months.</description>
    <arm_group_label>Cyclophosphamide</arm_group_label>
    <other_name>CTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with a diagnosis of FSGS.

          -  Patients with a proteinuria ≥ 3.5g/24h,and blood albumin &lt;30g/L,and Scr〈 2.3 mg/dl and
             eGFR&gt;30ml/min per 1.73m2.

          -  Patients who signed written informed consent form (patients less than 18 years old
             with their parents/legal representative's signatures), and have given their consent to
             follow all study procedures and follow-up.

        Exclusion Criteria:

          -  Patients who have received treatment of FK506 in latest 2 month or the cumulative dose
             CTX≥6 g.

          -  Patients who are known to be allergic to a macrolide.

          -  Patients who have active hepatitis.

          -  Patients who have impaired liver function, with ALT/GPT or AST/GOT twice more than the
             normal upper limit .

          -  Patients with blood leukocyte &lt; 3000/ul.

          -  Patients with kidney disease family history

          -  Patients with 2 type diabetes.

          -  Patients with obesity whose BMI&gt;28kg/m2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhihong Liu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2011</study_first_submitted>
  <study_first_submitted_qc>October 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2011</study_first_posted>
  <last_update_submitted>March 22, 2017</last_update_submitted>
  <last_update_submitted_qc>March 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing University School of Medicine</investigator_affiliation>
    <investigator_full_name>Zhi-Hong Liu, M.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>FSGS</keyword>
  <keyword>FK506</keyword>
  <keyword>CTX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

